The Expanded Partnership Between Cognizant and Gilead Sciences
Cognizant, a leading IT consulting firm, has announced an expansion of its existing partnership with biopharmaceutical company Gilead Sciences. This collaboration aims to deliver enhanced cost leadership and productivity for Gilead, while also extracting greater value from the relationship.
Utilizing Advanced Technologies
By harnessing the power of machine learning and generative AI within an agentic framework, Cognizant will focus on multiple use cases across customer service, employee interactions, and business value management. Gilead is expected to improve its efficiency by leveraging Cognizant’s expertise in AI and advanced technology applications.
Optimizing Financial Framework
Cognizant plans to deploy these technologies across Gilead’s value chain to help the company achieve significant benefits through a newly optimized financial framework. Over the past decade, Cognizant has supported Gilead in advancing its global IT infrastructure, platforms, applications, and advanced analytics to accelerate its digital transformation.
Enhanced Capabilities for Gilead
The extension of the partnership will create capacity for Gilead to focus on its mission of discovering and supplying critical medicines for cancer, HIV, and other diseases. Cognizant will leverage its Neuro AI generative AI platform to accelerate value creation, enhance IT and business processes, and improve operational efficiencies for Gilead.
Driving Innovation and Efficiency
Cognizant aims to transform the user experience of IT services for Gilead with custom-built Gen AI solutions, enabling the company to benefit from increased efficiency and a better user experience. Joydeep Ganguly, senior vice president and head of corporate operations and Interim CIO at Gilead, emphasized the importance of this partnership in advancing technology capabilities and driving cost leadership across technology programs.
Exciting Expansion of Partnership
Surya Gummadi, executive vice president and president of Cognizant Americas, expressed excitement about expanding the partnership with Gilead to deliver transformative treatments globally. The collaboration between the two companies aims to enhance user engagement, boost productivity, and drive cost savings for Gilead to focus on its critical work in preventing and treating life-threatening illnesses.
The Larger Trend
In addition to the expanded partnership with Gilead Sciences, Cognizant recently announced a strategic partnership with CrowdStrike to drive enterprise security transformation through cybersecurity services powered by the AI-native CrowdStrike Falcon platform. This collaboration aims to streamline security operations, mitigate threats, reduce complexity, and strengthen cybersecurity posture for organizations.
Last year, a worldwide IT outage caused disruptions in healthcare delivery after a misconfigured CrowdStrike Falcon update led to computer issues. Clinicians were forced to work manually without access to electronic health records and other critical IT systems. This incident highlights the importance of robust cybersecurity measures in healthcare.
Earlier this month, Gilead Sciences and LEO Pharma entered into a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for inflammatory diseases. This partnership demonstrates the industry’s commitment to advancing innovative treatments for patients in need.
